2023 ETF Series Trust - Brandes International ETF (BINV US) stock market data APIs
42.5574
-0.01(-0%)
as of May 13, 2026
Try our APIs with
free plan!
2023 ETF Series Trust - Brandes International ETF Financial Data Overview
Price chart is built with
Anychart
Prev. Close
42.5574
Open
42.5521
High
42.8574
Low
42.4588
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get 2023 ETF Series Trust - Brandes International ETF data using free add-ons & libraries
End-of-day & Earnings data
Get 2023 ETF Series Trust - Brandes International ETF Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
Get 2023 ETF Series Trust - Brandes International ETF End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
2023 ETF Series Trust - Brandes International ETF News
New
If You Own One of These ETFs, Fidelity Is About to Charge You $100 to Trade It
Starting June 1, Fidelity will charge a $100 fee on purchase trades on more than 120 exchange-traded funds (ETFs). It's one of the most investor-unfriendly decisions I've seen in a while. It started ...
If You Own One of These ETFs, Fidelity Is About to Charge You $100 to Trade It
Key Points Starting June 1, Fidelity will begin charging a $100 fee on purchase trades on more than 120 different ETFs. Many ETFs impacted are very small, but some big ones, such as the Roundhill Mag...
BioInvent to Present Data of BI-1808 Plus KEYTRUDA(R) (Pembrolizumab) in Recurrent Ovarian Cancer at the 2026 ASCO Annual Meeting
BioInvent International (STO:BINV) - BI-1808 multiplies by three the overall response rate as compared to pembrolizumab alone, supporting its potential to enhance antitumoral immune responses when com...
BioInvent Reports Promising Data from Ongoing Phase 2a study for BI-1808 with KEYTRUDA(R) (pembrolizumab) in Recurrent Ovarian Cancer
24% ORR for BI-1808 combined with pembrolizumab represents a meaningful improvement over pembrolizumab monotherapy in recurrent ovarian cancer (8% ORR in KEYNOTE-100) The combination demonstrated a fa...
Get 2023 ETF Series Trust - Brandes International ETF fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
